Cargando…
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Many human tumors are recognized by the adaptive immune system, but these spontaneous antitumor responses are typically inadequate to mediate regression. Blockade of immune regulatory “checkpoint” receptors such as cytotoxic T‐lymphocyte‐associated antigen 4 and programmed cell death 1 can unleash a...
Autores principales: | Reynolds, Kerry, Thomas, Molly, Dougan, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192661/ https://www.ncbi.nlm.nih.gov/pubmed/29853659 http://dx.doi.org/10.1634/theoncologist.2018-0174 |
Ejemplares similares
-
Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019) -
Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon
por: Khan, Shaheen, et al.
Publicado: (2020) -
A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
por: Lopez, Adriana T., et al.
Publicado: (2018) -
Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors
por: Drobni, Zsofia D, et al.
Publicado: (2021) -
Onset of Transient Sadness Following the Concomitant Use of a Triptan and
Selective Serotonin Reuptake Inhibitor/Serotonin Norepinephrine Reuptake Inhibitors
Therapy: A Case Report
por: Meng, Yuki, et al.
Publicado: (2021)